MAS
CYTK icon

Meeder Advisory Services’s Cytokinetics CYTK Stock Holding History

Meeder Advisory Services’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$325K Buy
3,820
+201
+6% +$14.4K 0.01% 529
2026
Q1 		$239K Sell
3,619
-190
-5% -$12.1K 0.01% 594
2025
Q4 		$242K Buy
+3,809
New +$237K 0.01% 590

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meeder Advisory Services's CYTK Position: Q2 2026 in Review

Meeder Advisory Services increased its Cytokinetics (CYTK) stake by 5.6% in Q2 2026, buying an estimated $14.4K and bringing the position to 3,820 shares worth $325K. The position accounts for 0.01% of the portfolio, ranked #529.

Meeder Advisory Services first reported a position in CYTK in Q4 2025 and has held it in 3 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Meeder Advisory Services held 3,820 shares of Cytokinetics worth $325K as of Q2 2026.
  • Meeder Advisory Services bought 201 Cytokinetics shares in Q2 2026, an estimated $14.4K.
  • Cytokinetics made up 0.01% of Meeder Advisory Services's portfolio in Q2 2026, its #529 holding.
  • Meeder Advisory Services first reported a position in Cytokinetics in Q4 2025 and has held it in 3 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Meeder Advisory Services's 13F filing for Q2 2026, filed 7 Aug 2026.